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ABSTRACT: An eﬃcient preparation of the antimalarial drug
candidate OZ439, which was obtained by integrating a
machine-assisted approach with batch processes, is reported.
This approach allows a rapid and cost-eﬀective production of
the key intermediates that were readily elaborated into the
target molecule.
Even in our highly developed society, malaria still representsa threat to humankind.1 The statistics for 2012 indicate
that this infection caused the deaths of more than half a million
people, with a further quarter billion being infected in most
cases by Plasmodium falciparum. Despite considerable research
eﬀorts, eﬀective antimalarial chemotherapy is still needed.2
While eﬃcacy, pharmacokinetics, and pharmacodynamics are
key issues to address, during the search for new potential
antimalarial treatments the primary criterion is related to the
cost of goods.3 New antimalarial agents therefore must be
available at low cost in order to match the economies mostly
aﬄicted by this disease. Drug resistance and the widespread use
of artemisinin and its derivatives (1a−d, Figure 1) are
important additional issues that need to be addressed.4,5
Climate change is also a problem, causing malaria to spread to
more heavily populated regions of the world.6
Recent investigations7 have led to the identiﬁcation of new
types of antimalarial agents containing a trioxolane unit as main
structural feature, with compound OZ277 (2) as one of the
most promising hits arising from this research.2a,8 Further
studies directed to improve the pharmacokinetic and
pharmacodynamic properties resulted in the identiﬁcation of
the more potent analogue OZ439 (3).2a,9 The important
property of 3 is that it provides a single oral dose treatment for
the total eradication of the parasite in humans; it is currently
undergoing phase IIa trials after having successfully completed
phase I clinical trials.2a,10
Despite the promising activity displayed by the drug
candidate, its preparation is not without problems. For example,
the reported synthesis of this compound relies on the use of
commercially available but relatively expensive 4-(4-
hydroxyphenyl)cyclohexan-1-one (4) and makes use of large
quantities of pentane, which is an undesirable solvent for the
preparation of the key trioxolane motif.11 Additionally, the
morpholine functionality is introduced using a potentially
genotoxic material in the last synthetic step (Scheme 1a).
Enabling technologies, in particular ﬂow chemistry, provide
beneﬁts and opportunities to devise new strategies for
molecular assembly. Additionally, the ﬂexibility of continuous
processing of material is highly amenable to later scale-up,
thereby making this an attractive approach. By integrating new
technologies with traditional batch methods, we aimed to
overcome some of the synthesis issues associated with the
preparation of OZ439. This could, in principle, pave the way
for low cost manufacturing in the countries where malaria is
prevalent. To this end, we have devised a route integrating the
advantages of batch- and continuous-processing methods
(Scheme 1b).12,13
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Figure 1. Artemisinin and its derivatives (1a−d), OZ277 (2), and
OZ439 (3).
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To achieve of our initial aim, we envisaged a new preparation
of the intermediate trioxolane 67,9 which would take advantage
of the use of enabling methods. Key transformations in this new
strategy would be the selective reduction of readily available
biphenol 7 to selectively aﬀord 4-(4-hydroxyphenyl)cyclohexan-
1-one (4) and subsequent reaction of this ketone with the O-
methyl oxime 5 by co-ozonolysis. We would then install the
amide substituent (to furnish 13) and eventually reveal the ﬁnal
product, OZ439 (3), via an amide reduction process.
Previous work from our group has shown the extreme
ﬂexibility of a small footprint platform (HEL FlowCAT)14,15
for liquid/gas reactions under trickle heterogeneous catalysis
conditions. Our approach for the selective reduction of 7 to 4
started with the screening of relevant parameters, including
catalyst, temperature, gas feed, liquid feed, and substrate
concentration as well as solvent, which are all conveniently
achieved on this machinery.16
Catalyst screening allowed us to identify Pd/C 20 mol % as a
suitable material for the transformation. Using other metal
catalysts (i.e., Rh and Pt) or lowering the loading of Pd (5, 10,
or 15 mol %) reduced the selectivity as well as the conversion.
Similarly, negative results were obtained when moving from
Pd/C to Pd/Al2O3. We also found that although the use of
EtOH as solvent gave the best results in terms of conversion,
the use of EtOH/H2O (1:1, v/v) as solvent mixture yielded the
best result in terms of selectivity. The concentration was set at
0.05 M (equating to a throughput of 3 mmol h−1) to avoid any
precipitation of starting material 7 or product 4. Temperature
was another important factor to consider in the optimization
because higher or lower temperatures either reduced the
selectivity or decreased the conversion of 7 to 4, thereby
increasing the amount of the otherwise minor byproducts 8 and
9 (Scheme 2). Similar behavior was observed for the amount of
H2 fed into the system, with ﬂow rates above and below 0.1 L
min−1 giving disruption in terms of both selectivity and
conversion. Under the optimized conditions, a solution of 7 in
EtOH/H2O (1:1 v/v, 0.05 M) was passed through a packed
bed reactor (3 mL internal volume) containing the
heterogeneous catalyst (Pd/C, 20 mol %) at 1.00 mL min−1,
feeding the reactor with 0.1 L min−1 of H2, while keeping the
pressure of the whole system at 5 bar. With this protocol, we
were able to quickly isolate pure material in an appreciable yield
of 58% after recrystallization from the reaction mixture (>95%
purity as determined by NMR). By simply extending the
reaction run time, we successfully delivered around 2 g of
compound 4 in 5 h, with this reactor setup. This result clearly
highlights the advantages of continuous processing compared
to the batch protocol.17
With an optimized protocol for preparation of ketone 4 in
hand, we then developed a method for its continuous
acetylation. In a very straightforward manner, we were able to
perform the desired transformation in quantitative yield.
Suitable conditions were soon found whereby a solution of
phenol 4 in CH2Cl2 was combined at a T-piece with a stream of
acetic anhydride (1.5 equiv), DMAP (5 mol %), and Et3N (4.5
equiv) in CH2Cl2 (combined ﬂow rate 0.8 mL min
−1) and
reacted in a 10 mL PFA coil at rt (Scheme 3). Simple ﬁltration
through silica and evaporation of the reactor output gave 10,
which could be used in the next stage without a need for further
puriﬁcation.16
Next, we commenced an investigation of the Griesbaum
oxidation reaction under ﬂow conditions.18 The co-ozonolysis
reaction between ketones and alkylated oximes had been
reported in 1997 by Griesbaum et al. as an eﬃcient
methodology for the preparation of 1,2,4-trioxolane.19,20 We
began by adapting a ﬂow set up which had been previously
proven to eﬀectively aﬀord the continuous ozonolysis of
oleﬁns.21 The investigation of processing conditions for the
reaction was carried out using 4-phenylcyclohexanone 11 as a
commercially available model substrate.15 A solution containing
the oxime 5 and the ketone 11 (X = H) in EtOAc was reacted
with a stream of ozone. Both the liquid and gas feed were
adjusted to maximize the reaction yield.16 Experiments
conducted with an excess of ketone counterpart partner
aﬀorded the reaction product in moderate yield while an
excess of oxime with respect to the ketone aﬀorded a great
Scheme 1. (a) Previous Preparation of OZ439; (b) This
Work
Scheme 2. Selective Continuous Hydrogenation of 4,4′-
Biphenol 7 To Prepare 4
Scheme 3. Flow Acetylation of 4-(4-
Hydroxyphenyl)cyclohexan-1-one 4 to aﬀord 10
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improvement of reaction yield, leading to isolation of 76% of
the desired compound 12 after puriﬁcation (Scheme 4). The
continuous process was run for 45 min without issue.
Unfortunately, under longer reaction times blockages occurred
due to the slight evaporation of the solvent. This was easily
avoided by decreasing the concentration of oxime 5 (from 0.4
to 0.2 M) and ketone 11 (from 0.2 to 0.1 M) while increasing
both the liquid and gaseous ﬂow rates (1 mL min−1 and 1 L
min−1, respectively) in order to keep an identical throughput
for the reaction system.
Under these diluted conditions we were able to continuously
run the reaction without any clogging issue for over 3 h,
isolating 78% of the model product with a calculated
throughput of 1.6 g·h−1 (equating to 38.4 g·d−1).
We then assessed the suitability of this particular reactor
setup (Scheme 4) for the ﬂow co-ozonolysis between 5 and 10.
Pleasingly, the reaction proceeded nicely and allowed the
isolation of the desired 1,2,4-trioxolane 6 in 70% yield (9:1 cis−
trans selectivity toward the desired product). This yield equates
to a production of 1.9 g·h−1 (45.6 g·d−1). The procedure clearly
surpasses limitations and safety issues associated with operating
with ozone in batch mode,20 in particular, by avoiding the use
of pentane as solvent by replacing it with ethyl acetate.
Additionally, this approach ensures continuous production of
the desired material in good yield. Once an eﬃcient synthesis of
this key fragment 6 was assured, the compound was subjected
to reaction conditions previously reported in the literature for
the cleavage of the acetyl group. While the formed phenoxide
anion can be reacted with 4-(2-chloroethyl)morpholine
aﬀording OZ439 (3) in excellent yield,16 we wanted to
examine whether an alternative route that would avoid the
use of the genotoxic agent 4-(2-chloroethyl)morpholine was
feasible (Scheme 5).
We designed a simple alternative route to avoid the use of
this material that consisted of two steps: the generation of the
amide intermediate 13 and its reduction to produce the API
OZ439 (3). We began with the preparation of 13 via a
straightforward nucleophilic substitution of the in situ
deprotected phenolate in the presence of 4-(chloroacetyl)-
morphine. This product (13) was then subjected to a selective
reduction of the amide moiety. We noticed a remarkable
sensitivity associated with the trioxolane ring of 13, as most
reducing reagents (i.e., BH3·THF complex, BH3·SMe2 complex,
NaBH4, LiAlH4, and Tf2O/NaBH4) resulted in both reduction
of the amide group and cleavage of the trioxolane moiety. To
our delight, however, using a Zn-catalyzed amide reduction in
the presence of triethoxysilane,22 we found that OZ439 (3)
could be obtained in 86% isolated yield without disruption of
the trioxolane system.
In summary, we have developed a more robust and eﬃcient
protocol for the synthesis of the antimalarial drug candidate
OZ439 (3), using a machine-assisted protocol. Flow
technologies were successfully applied to implement three
key transformations (i.e., selective partial hydrogenation,
acetylation reaction of the phenol group, and Griesbaum co-
ozonolysis) surpassing limitations previously observed for batch
process while aﬀording a very attractive outcome in terms of
continuous processing. The new route avoids the use of the
genotoxic 4-(2-chloroethyl)morpholine. The development of a
fully continuous synthesis of OZ439 (3) is currently under
investigation in our laboratories.
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